Amneal LLC

Amneal LLC is a fully-integrated biopharmaceutical company, commonly known as Amneal Pharmaceuticals. Founded in 2002 by brothers Chirag and Chintu Patel, the company is headquartered in Bridgewater, New Jersey. Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) is a publicly traded entity, following a 2018 merger with Impax Laboratories, Inc. As of May 2026, Amneal has approximately 8,500 employees and reported a trailing twelve-month revenue of $3.05 billion, with a market capitalization of $4.08 billion.

Amneal Pharmaceuticals develops, manufactures, and distributes generic and specialty pharmaceutical products. Its Generics segment includes a diverse portfolio of over 270 products, encompassing oral solids and liquids, injectables, ophthalmics, topicals, softgels, inhalation products, and transdermals, many of which are complex or high-barrier-to-entry products. The Specialty segment focuses on branded pharmaceutical products primarily for central nervous system and endocrine disorders, including treatments for Parkinson's disease (e.g., Rytary®, Crexont®), migraines (e.g., Brekiya®), and hypothyroidism (Unithroid®). Amneal is also expanding its presence in biosimilars, with several approvals for cancer-related treatments.

Amneal LLC primarily operates as an operating company. Its patent litigation posture, based on the provided data, is defensive, appearing as a defendant in all of its tracked cases. This indicates the company is defending against allegations of patent infringement, typical for a generic and specialty pharmaceutical manufacturer.

The sole tracked case, Amgen Inc. v. Amneal LLC et al., filed in the District of New Jersey in 2025, reflects this defensive posture. The District of New Jersey is a common venue for patent litigation involving pharmaceutical companies, particularly those with a significant presence or headquarters in the state, like Amneal. This case suggests a dispute over a pharmaceutical patent, likely concerning one of Amneal's generic or biosimilar product offerings.